TY - JOUR
T1 - High-dose and low-dose combined oral contraceptives
T2 - protection against epithelial ovarian cancer and the length of the protective effect
AU - Rosenblatt, Karin A.
AU - Thomas, David B.
AU - Noonan, Elizabeth A.
N1 - Funding Information:
Acknowledgements--This research was supported by grants from the “Direction G&&ale de la Sante” (8962/406, 90621481,9 062/824) and from the “Direction G&&ale des Affaires Sociales” (8961/800)d u Minis&e de la Communaud Francaise de Belgique. The authors thank Christine Farvacques, Christine Thiriart, Cathy Van Heer and Marie-Anne Vivier for their participation in this study.
PY - 1992
Y1 - 1992
N2 - The relations between use of high-dose and low-dose combined oral contraceptives and epithelial ovarian cancer were compared in an international hospital-based case-control study. 393 cases from seven countries were compared with 2561 matched controls. The odds ratio (OR) was somewhat lower for women who used high-dose oestrogen oral contraceptives (OR = 0.68) than for women who used low-dose preparations (OR = 0.81) although the difference could have occurred by chance. After controlling for time since last use, risk was slightly lower for long-term users of high-dose preparations than for long-term users of low-dose pills. Both high-dose and low-dose oral contraceptives protect against ovarian cancer, but the degree of protection may be slightly weaker for the newer, low-dose products.
AB - The relations between use of high-dose and low-dose combined oral contraceptives and epithelial ovarian cancer were compared in an international hospital-based case-control study. 393 cases from seven countries were compared with 2561 matched controls. The odds ratio (OR) was somewhat lower for women who used high-dose oestrogen oral contraceptives (OR = 0.68) than for women who used low-dose preparations (OR = 0.81) although the difference could have occurred by chance. After controlling for time since last use, risk was slightly lower for long-term users of high-dose preparations than for long-term users of low-dose pills. Both high-dose and low-dose oral contraceptives protect against ovarian cancer, but the degree of protection may be slightly weaker for the newer, low-dose products.
UR - http://www.scopus.com/inward/record.url?scp=0026662478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026662478&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(92)90026-X
DO - 10.1016/0959-8049(92)90026-X
M3 - Article
C2 - 1389530
AN - SCOPUS:0026662478
SN - 0959-8049
VL - 28
SP - 1872
EP - 1876
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 11
ER -